TGF-Beta Inhibitor Pipeline Insight

DelveInsight’s, “TGF-Beta Inhibitor Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in TGF-Beta Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

TGF-Beta Inhibitor Understanding

TGF-Beta Inhibitor Overview

Transforming Growth Factor-beta (TGF-β) inhibitors are therapeutic agents designed to block or modulate the activity of the TGF-β signaling pathway, which plays a critical role in regulating cell growth, differentiation, immune responses, tissue repair, and fibrosis. Although TGF-β normally helps maintain tissue homeostasis, abnormal overactivation of this pathway has been implicated in numerous diseases, including cancer, fibrotic disorders, autoimmune diseases, and ophthalmic conditions.

TGF-β inhibitors exert their therapeutic effects by blocking or modulating the TGF-β signaling pathway, thereby preventing the downstream cellular processes associated with fibrosis, inflammation, immune suppression, and pathological tissue remodeling. Under normal physiological conditions, TGF-β ligands bind to TGF-β type II receptors, which subsequently recruit and activate type I receptors, leading to phosphorylation of intracellular SMAD proteins (primarily SMAD2 and SMAD3). These activated SMAD complexes translocate to the nucleus and regulate the transcription of genes involved in extracellular matrix production, cell proliferation, differentiation, epithelial–mesenchymal transition (EMT), angiogenesis, and immune regulation. In disease states, excessive TGF-β signaling promotes abnormal collagen deposition, fibroblast activation, tissue scarring, tumor progression, and immune evasion.

TGF-β inhibitors interfere with this cascade through multiple mechanisms, including neutralizing TGF-β ligands with monoclonal antibodies, preventing ligand–receptor interactions, inhibiting TGF-β receptor kinase activity using small-molecule inhibitors, or blocking downstream SMAD signaling. Some therapies also employ antisense oligonucleotides or ligand traps to reduce TGF-β expression or bioavailability. By suppressing aberrant TGF-β signaling, these inhibitors help reduce fibrosis, inhibit tumor microenvironment remodeling, restore anti-tumor immune responses, and limit pathological tissue damage in disorders such as cancer, pulmonary fibrosis, glaucoma, diabetic retinopathy, and other chronic inflammatory or fibrotic diseases.

TGF-β inhibitors have broad therapeutic applications across oncology, fibrotic disorders, autoimmune diseases, and ophthalmology because dysregulated TGF-β signaling contributes to pathological tissue remodeling, immune suppression, inflammation, and fibrosis. In oncology, TGF-β inhibitors are being investigated and developed to counteract tumor progression, metastasis, epithelial–mesenchymal transition (EMT), angiogenesis, and immune evasion within the tumor microenvironment. By restoring anti-tumor immune activity, these agents are also being explored in combination with immune checkpoint inhibitors for the treatment of solid tumors such as pancreatic cancer, non-small cell lung cancer, breast cancer, and colorectal cancer. In fibrotic diseases, TGF-β inhibition is considered a promising strategy because TGF-β is a key driver of fibroblast activation and extracellular matrix deposition.

Consequently, these therapies are under investigation for idiopathic pulmonary fibrosis, liver fibrosis, renal fibrosis, systemic sclerosis, and cardiac fibrosis, where they may help reduce scar formation and preserve organ function. In autoimmune and inflammatory disorders, modulation of TGF-β signaling may help regulate abnormal immune responses associated with diseases such as rheumatoid arthritis, inflammatory bowel disease, and certain connective tissue disorders. In ophthalmology, TGF-β inhibitors are being studied for conditions including glaucoma, proliferative vitreoretinopathy, corneal scarring, and diabetic retinopathy, where excessive TGF-β activity contributes to fibrosis, extracellular matrix accumulation, and abnormal wound healing.

"TGF-Beta Inhibitor Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TGF-Beta Inhibitor pipeline landscape is provided which includes the disease overview and TGF-Beta Inhibitor treatment guidelines. The assessment part of the report embraces, in depth TGF-Beta Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TGF-Beta Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest TGF-Beta Inhibitor pipeline insights, emerging therapies, and clinical advancements shaping the future of fibrosis-targeted treatment in 2026.

TGF-Beta Inhibitor Pipeline Report Highlights

The TGF-Beta Inhibitor companies and academics are working to assess challenges and seek opportunities that could influence TGF-Beta Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve TGF-Beta Inhibitor.

TGF-Beta Inhibitor Emerging Drugs Analysis

This segment of the TGF-Beta Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TGF-Beta Inhibitor Emerging Drugs

OT-101: Oncotelic Inc.

OT-101 (Trabedersen) is a novel phosphorothioate antisense oligodeoxynucleotide targeting TGF-β2 mRNA. TGF-β2 plays a crucial role in tumor immune evasion and progression. OT-101 inhibits TGF-β2 at the mRNA level, reprogramming the tumor microenvironment. It converts immunosuppressive M2 macrophages into pro-inflammatory M1 macrophages, enhances anti-tumor immunity, and may synergize with PD-1 inhibitors such as pembrolizumab. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Glioblastoma.

AdAPT-001: EpicentRx, Inc

AdAPT-001, EpicentRx’s proprietary 2-in-1 biologic, whose activity was highlighted in a 2024 ASCO podium presentation, is designed to express a potent TGFβR inhibitor for local TGFβ neutralization, decreased Treg cell function, and superior therapeutic responses in combination with checkpoint inhibitors for several tumor types including STS, colorectal cancer, breast cancer and hepatocellular carcinoma. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Solid Tumors.

IOA-359: iOnctura

IOA-359, a novel small molecule TGF-β pathway inhibitor, in solid tumors. By characterising the resistance mechanisms that typically arise when targeting the TGF-β pathway alone, our data-driven precision oncology methods are being used to design novel combination treatments that promise to override tumor survival pathways. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Solid Tumors.

Further product details are provided in the report……..

TGF-Beta Inhibitor Drug Therapeutic Assessment

This segment of the report provides insights about the different TGF-Beta Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major TGF-Beta Inhibitor Players in TGF-Beta Inhibitor

There are approx. 10+ key companies which are developing the therapies for TGF-Beta Inhibitor. The companies which have their TGF-Beta Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Oncotelic Inc.

TGF-Beta Inhibitor Clinical Trial Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

TGF-Beta Inhibitor Drug Route of Administration

TGF-Beta Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

TGF-Beta Inhibitor Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

TGF-Beta Inhibitor Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TGF-Beta Inhibitor Clinical Trial Activities

The TGF-Beta Inhibitor pipeline report provides insights into different TGF-Beta Inhibitor clinical trials within phase II, I, preclinical and discovery stage. It also analyses TGF-Beta Inhibitor therapeutic drugs key players involved in developing key drugs.

TGF-Beta Inhibitor Pipeline Development Activities

The TGF-Beta Inhibitor clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TGF-Beta Inhibitor drugs.

TGF-Beta Inhibitor Pipeline Report Insights

• TGF-Beta Inhibitor Pipeline Analysis
• TGF-Beta Inhibitor Therapeutic Assessment
• TGF-Beta Inhibitor Unmet Needs
• Impact of TGF-Beta Inhibitor Drugs

TGF-Beta Inhibitor Pipeline Report Assessment

• TGF-Beta Inhibitor Pipeline Product Profiles
• TGF-Beta Inhibitor Therapeutic Assessment
• TGF-Beta Inhibitor Pipeline Assessment
• TGF-Beta Inhibitor Inactive drugs assessment
• TGF-Beta Inhibitor Market Unmet Needs

Discover actionable insights into the TGF-Beta Inhibitor market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The TGF-Beta Inhibitor Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing TGF-Beta Inhibitor drugs?
• How many TGF-Beta Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TGF-Beta Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TGF-Beta Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for TGF-Beta Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

TGF-Beta Inhibitor Key Players

• Oncotelic Inc.
• EpicentRx, Inc
• iOnctura
• Scholar Rock, Inc.
• Bristol Myers Squibb

TGF-Beta Inhibitor Key Products

• OT-101
• AdAPT-001
• IOA-359
• SRK-373
• BMS 986416

Explore comprehensive insights into TGF-Beta Inhibitor epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.